Maven Securities’s Innate Pharma IPHA Stock Holding History

Maven Securities’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-130,000	Closed	-$836K	–	369
2019 Q4	$836K	Buy	+130,000	New	+$799K	0.08%	199

Other funds holding IPHA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Maven Securities's IPHA Position: Q1 2020 in Review

Maven Securities sold out of Innate Pharma (IPHA) in Q1 2020, closing a stake of 130,000 shares — an estimated $836K sold.

Maven Securities first reported a position in IPHA in Q4 2019 and held it in 1 quarter. The position peaked at $836K in Q4 2019. 10 funds tracked by Wall St. Rank hold IPHA as of Q1 2020.

Maven Securities reported no remaining Innate Pharma position as of Q1 2020 after selling out during the quarter.
Maven Securities sold 130,000 Innate Pharma shares in Q1 2020, an estimated $836K.
Maven Securities first reported a position in Innate Pharma in Q4 2019 and held it in 1 quarter.
Maven Securities's Innate Pharma position peaked at $836K in Q4 2019.
10 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2020.

Based on Maven Securities's 13F filing for Q1 2020, filed 15 May 2020.